Elypta
The company develops a liquid biopsy platform that measures the GAGome, a set of biomarkers related to tumor metabolism, to detect cancer signatures noninvasively. Their primary product is the MIRAM Kit, which utilizes machine learning to analyze urine and blood samples for early cancer detection and recurrence monitoring. The technology is currently being applied in clinical studies for kidney cancer follow-up and multi-cancer screening for high-risk populations.
Healthtech
Diagnostics
Biotechnology
Oncology
Funding summary
- Total raised
- €26.9M
- Funding rounds
- 3
Investors in Elypta
Investors on record for Elypta. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Elypta?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors